v3.26.1
Collaborative and Other Relationships - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 200 Months Ended
May 11, 2025
Nov. 30, 2009
Jun. 30, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
License Agreements                  
Contract dispute settlement     $ 0 $ 242,251   $ 0 $ 242,251    
Total revenues     1,674,039 1,215,529   2,946,715 2,268,427    
United States                  
License Agreements                  
Total revenues     1,560,110 1,132,353   2,731,578 2,113,910    
JAKAFI                  
License Agreements                  
Total revenues     816,659 763,788   1,574,414 1,473,200    
Novartis | JAKAFI                  
License Agreements                  
Royalties payable         $ 537,100        
Litigation settlement, amount awarded to other party $ 280,000                
Royalty rate payable, percent reduction (as a percent) 50.00%                
Decrease in royalties payable         $ 14,900        
Contract dispute settlement       242,200     242,200    
Novartis | JAKAFI | United States                  
License Agreements                  
Royalties payable     20,000     20,000   $ 20,000 $ 20,300
Total revenues     20,000 18,700   36,100 48,500    
Novartis | JAKAVI                  
License Agreements                  
Total revenues     124,200 109,700   229,700 201,900    
Novartis | TABRECTA                  
License Agreements                  
Total revenues     $ 6,700 $ 6,600   $ 12,700 $ 13,000    
Maximum | Novartis | JAKAVI                  
License Agreements                  
Royalty payments on future global net sales (as a percent)           14.00%      
Minimum | Novartis | JAKAVI                  
License Agreements                  
Royalty payments on future global net sales (as a percent)           12.00%      
Development Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               157,000  
Development Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   $ 174,000              
Regulatory Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               345,000  
Regulatory Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   495,000              
Commercialization Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               $ 200,000  
Commercialization Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   500,000              
Development and Regulatory Milestones | Maximum | Novartis | GVHD                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   $ 75,000